Search Result

Results for "

metastatic pancreatic cancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Akt (1) Antibiotic (2) Apoptosis (1) Autophagy (1) Bacterial (2) Cadherin (1) Casein Kinase (1) CD3 (1) Drug Derivative (1) Glutaminase (2) HIF/HIF Prolyl-Hydroxylase (1) Histone Acetyltransferase (1) ICMT (1) Influenza Virus (2) PAI-1 (2) PROTACs (1) Reference Standards (1) SARS-CoV (1) Ser/Thr Protease (2) TGF-beta/Smad (1) TNF Receptor (1) Transmembrane Glycoprotein (2) Wnt (1)
By Research Areas:	Cancer (14) Infection (4) Inflammation/Immunology (2)

By Targets:

ADC Antibody (1)

Akt (1)

Antibiotic (2)

Apoptosis (1)

Autophagy (1)

Bacterial (2)

Cadherin (1)

Casein Kinase (1)

CD3 (1)

Drug Derivative (1)

Glutaminase (2)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Acetyltransferase (1)

ICMT (1)

Influenza Virus (2)

PAI-1 (2)

PROTACs (1)

Reference Standards (1)

SARS-CoV (1)

Ser/Thr Protease (2)

TGF-beta/Smad (1)

TNF Receptor (1)

Transmembrane Glycoprotein (2)

Wnt (1)

By Research Areas:

Cancer (14)

Infection (4)

Inflammation/Immunology (2)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-108357

6-Diazo-5-oxo-L-nor-Leucine Maximum Cited Publications 14 Publications Verification L-6-Diazo-5-oxonorleucine; DON	Glutaminase Bacterial Influenza Virus Antibiotic	Infection Cancer
6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine; DON) is a glutamine antagonist that irreversibly inhibits the catabolic effect of glutamine. 6-Diazo-5-oxo-L-nor-Leucine shows good anticancer activity (especially in pancreatic cancer) and reduces the self-renewal potential and metastatic capacity of tumour cells. 6-Diazo-5-oxo-L-nor-Leucine also possesses antibacterial and antiviral activity .

HY-P99049

Sotigalimab APX005M; APX005M; EPI-0050	TNF Receptor	Inflammation/Immunology
Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .

HY-P9974

Vantictumab 1 Publications Verification OMP-18R5	Wnt	Cancer
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .

HY-16511

Upamostat 1 Publications Verification WX-671	PAI-1 Ser/Thr Protease	Infection Cancer
Upamostat (WX-671), a prodrug of WX-UK1, is an orally active serine protease inhibitor. Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, blocking the plasminogen activation process mediated by it, thereby suppressing the invasion, migration and metastasis of tumor cells. Upamostat can be used in the research of metastatic breast cancer and locally advanced pancreatic cancer .

HY-170859

AH078	PROTACs Casein Kinase	Cancer
AH078 is a PROTAC-based CK1δ/ε degrader (DC₅₀=0.55 μM, D_max=70%) that lacks subtype selectivity between CK1δ and CK1ε. AH078 induces target protein degradation either by recruiting the CUL4-CRBN E3 ligase complex and proteasome, or via the VHL- and ubiquitin-dependent pathway. AH078 also exhibits selectivity for CK1α, and is widely applicable to research related to colon cancer, pancreatic cancer, breast cancer, ovarian cancer, chronic lymphocytic leukemia, acute myeloid leukemia, glioma, and metastatic breast adenocarcinoma .

HY-P991190

Rilogrotug AV-380	TGF-beta/Smad	Cancer
Rilogrotug (AV-380) is a humanized IgG1 monoclonal antibody targeting GDF15 .

HY-146695

S100P-IN-1	Drug Derivative	Cancer
S100P-IN-1 (Compound 4) is a S100P inhibitor with an IC₅₀ of 22.7 nM. S100P-IN-1 shows anti-metastatic effects on pancreatic cancer cells .

HY-P990730

Cabotamig ARB202	CD3 Cadherin	Cancer
Cabotamig is a humanized bispecific T-cell engager antibody targeting CDH17/CD3. Cabotamig is generated from anti-CDH17 monoclonal ARB102 by linking a CD3-binding scFv in the format of IgG4-scFv. Cabotamig can be used for the research of cancer, such as gastric cancer and colon cancers .

HY-123009

KCN1	HIF/HIF Prolyl-Hydroxylase Histone Acetyltransferase	Cancer
KCN1 is a p300/HIF-1α interaction inhibitor. KCN1 inhibits HIF transcriptional activity by binding to the CH1 domain of p300 and preventing the p300/HIF-1α assembly. KCN1 exerts antitumor activities through cell cycle arrest .

HY-N12677

Isocannflavin B Caflanone; FBL-03G	SARS-CoV Apoptosis Autophagy Akt	Infection Cancer
Isocannflavin B (Caflanone) is a flavonoid compound. Isocannflavin B exhibits anti-tumor and anti-viral activities. Isocannflavin B induces apoptosis, autophagy and cell cycle arrest in tumor cells, and inhibits cell proliferation. Isocannflavin B inhibits HCoV-OC43. Isocannflavin B can be used in research related to cancer and COVID-19 .

HY-108357R

6-Diazo-5-oxo-L-nor-Leucine (Standard) L-6-Diazo-5-oxonorleucine (Standard); DON (Standard)	Reference Standards Glutaminase Bacterial Influenza Virus Antibiotic	Infection Cancer
6-Diazo-5-oxo-L-nor-Leucine (Standard) is the analytical standard of 6-Diazo-5-oxo-L-nor-Leucine. This product is intended for research and analytical applications. 6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine; DON) is a glutamine antagonist that irreversibly inhibits the catabolic effect of glutamine. 6-Diazo-5-oxo-L-nor-Leucine shows good anticancer activity (especially in pancreatic cancer) and reduces the self-renewal potential and metastatic capacity of tumour cells. 6-Diazo-5-oxo-L-nor-Leucine also possesses antibacterial and antiviral activity[1][2][3].

HY-149709

ICMT-IN-35	ICMT	Cancer
ICMT-IN-35 (compound 10n) is a FTPA-triazole compound and ICMT inhibitor (IC₅₀=0.8 μM). ICMT-IN-35 is taken up by mammalian cells and can prevent K-Ras membrane localization and induce K-Ras mislocalization. Furthermore, ICMT-IN-35 is selectively cytotoxic against ICMT ^+/+ MEF cells and has low micromolar activity (IC₅₀=0.8 μM) against metastatic pancreatic cancer cell lines .

HY-16512

Upamostat hydrogen sulfate WX-671 hydrogen sulfate	PAI-1 Ser/Thr Protease	Cancer
Upamostat (WX-671) hydrogen sulfate, a prodrug of WX-UK1 (HY-100415), is an orally active serine protease inhibitor. Upamostat hydrogen sulfate inhibits the urokinase-type plasminogen activator (uPA) system, blocking the plasminogen activation process mediated by it, thereby suppressing the invasion, migration and metastasis of tumor cells. Upamostat hydrogen sulfate can be used in the research of metastatic breast cancer and locally advanced pancreatic cancer .

HY-P992459

SGM-101 Antibody	ADC Antibody Transmembrane Glycoprotein	Cancer
SGM-101 Antibody is a chimeric monoclonal antibody targeting carcinoembryonic antigen (CEA). SGM-101 Antibody can serve as a tumor-specific fluorescent imaging probe after being covalently conjugated with the near-infrared fluorescent dye BM104 . SGM-101 Antibody accumulates in CEA-positive tumor tissues via antigen-antibody specific binding, and emits near-infrared fluorescence to enable imaging of tumor lesions. SGM-101 Antibody can be used in research related to gastric cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, breast cancer, peritoneal carcinomatosis, and liver metastases .

HY-P991896

AT1412 AT14-012	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells ^[1] .

Cat. No.	Product Name	Target	Research Area	Image